MOTS-c Legal Status, FDA 503A Category, and Compounding Access

The short version

Here is the MOTS-c legal status in plain terms, with the momentum and the limits both stated. Right now, MOTS-c is a research peptide — it is not an FDA-approved drug for any condition, and it is sold only for laboratory research. But access is under active FDA review and may expand in 2026: MOTS-c is individually named on the published agenda of an FDA advisory-committee meeting scheduled for July 23-24, 2026, where it is one of the substances "being considered for inclusion on the 503A Bulks List" — the list of ingredients that pharmacies may compound into patient-specific medicines. That is a scheduled discussion, not a listing decision, and not a change in today's status. This page is general information, not medical or legal advice, and not an offer to sell or supply anything.

The current fact

MOTS-c — a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region — is a research peptide and is not an FDA-approved drug for any indication.

Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance (an active ingredient used as a starting material, rather than a finished FDA-approved drug) may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Substances not yet on that list are evaluated by FDA through a public nomination process, informed by the Pharmacy Compounding Advisory Committee (PCAC).

MOTS-c is one of the bulk drug substances FDA has scheduled for PCAC evaluation. Being under evaluation is not the same as being on the bulks list, and it is not the same as being approved for compounding. MOTS-c has not been assigned a placement on a final bulks list; its present-tense status is research peptide, not FDA-approved, scheduled for PCAC evaluation.

FDA 503A Compounding Context

Two sections of the Act govern compounding, and both are relevant context for any peptide. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers registered "outsourcing facilities" that compound larger batches under cGMP-style oversight and FDA registration and inspection.

The gate, in both, is ingredient eligibility. A compounder may use a bulk substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or is on the applicable FDA bulks list; otherwise the substance must be nominated and evaluated by FDA. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by PCAC — and being discussed by PCAC is a step in evaluation, not a final listing decision. FDA approval of a finished drug is a separate question from whether a bulk substance may be compounded; MOTS-c is not an FDA-approved drug. This is the FDA 503A compounding context as it applies to a substance still under evaluation.

A note on category: this digest does not assign MOTS-c a numbered 503A category. FDA's per-substance category determinations published for certain other peptides are specific to those substances; MOTS-c's status here is stated exactly as scheduled for PCAC evaluation, not as a category placement.

What 2026 may bring — and what it is not

The forward-leaning fact: MOTS-c is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List." It is listed for evaluation in both its free-base and acetate forms, and the same agenda also lists BPC-157, TB-500, and KPV.

What that means: MOTS-c's eligibility for compounding is genuinely on the table and being actively evaluated, which is more than can be said for most research peptides. What it does not mean: it is a scheduled evaluation and discussion only. It is not a listing decision, not a reclassification, and not a change in MOTS-c's current status. A PCAC discussion is advisory; the outcome is unknown and must not be assumed, stated, or dated. Reports circulating about broader 2026 peptide reclassifications or removals are, as of this writing, unconfirmed by any authoritative FDA source, and this page treats them as exactly that — unconfirmed.

How legally compounded access works

In general terms, a legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility.

Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued. It does not change which substances are eligible to be compounded, and it does not remove the requirement for a legitimate prescriber-patient relationship and a valid prescription.

The ingredient-eligibility caveat is decisive: a compounder may use an active ingredient only if it is eligible under the 503A/503B bulk-substance rules, and an ingredient FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands. This is described here as general information about the regulatory landscape — not medical or legal advice, not a protocol, and not an offer to sell or supply any substance. This site names no pharmacy, clinic, telehealth provider, or vendor.

Is MOTS-c Legal?

MOTS-c is not an FDA-approved drug and is sold only as a research chemical for laboratory use; it is not approved for human use. It is individually named on the FDA PCAC agenda for July 23-24, 2026 for evaluation as a possible 503A bulks-list substance — a scheduled discussion, not a change in status. Legal status for purchase varies by jurisdiction.

Is MOTS-c Legal to Buy?

MOTS-c is not approved by the FDA for human use and is sold only as a research chemical for laboratory use. It is treated as a prohibited substance in elite sport. Legal status for purchase varies by jurisdiction.

Can I Get MOTS-c Over the Counter?

MOTS-c is not an FDA-approved drug or an approved over-the-counter product; it is sold only for laboratory research. There is no approved indication, formulation, or dose.

Can You Get MOTS-c From a Compounding Pharmacy?

Whether a 503A compounding pharmacy may use a given ingredient depends on that ingredient's eligibility (USP/NF monograph, component of an approved drug, or on the FDA bulks list). MOTS-c is not on a final bulks list; it is scheduled for PCAC evaluation on July 23-24, 2026, which is a step in evaluation, not eligibility for routine compounding. Any compounded preparation also requires a licensed-prescriber evaluation and a valid patient-specific prescription.

What Is the FDA 503A Status of MOTS-c?

MOTS-c is a research peptide, not an FDA-approved drug, and is scheduled for PCAC evaluation as a candidate for the 503A bulks list at the July 23-24, 2026 meeting. This digest does not assign it a numbered 503A category; its status is "under evaluation," which is distinct from being on the bulks list or approved for compounding.

Anti-doping status

Separate from FDA status, MOTS-c is treated as a prohibited substance in elite sport. Anti-doping bodies such as USADA and WADA classify MOTS-c among peptide and metabolic-modulator agents prohibited at all times, and athlete use can result in sanctions. This is a sport-eligibility fact, not a statement about general legality, and it is independent of the FDA compounding question above.